Polymerase Chain Reaction Respiratory Viral Panel Testing
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.181 alerts
Get alerted when Policy CP.MP.181 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coding guidance for multiplex respiratory PCR (respiratory viral panel) testing for non-Medicare plans affiliated with Centene Corporation; defines when panels of varying sizes are considered medically necessary and lists supporting CPT and ICD-10 codes.
No material clinical or coverage changes in this revision.
Medical Necessity Criteria
Initial criteria for panels with 5 or fewer targets
RVPs with five pathogens or fewer are considered medically necessary when ALL of the following are met:
From I.A.1-2
From I.B
From I.C
From I.D
From I.E
From I.F
From I.G
Criteria for panels with 6 or more targets
RVPs with six pathogens or more are considered medically necessary when the Section I criteria are met AND any ONE of the following:
II.A.1
II.A.2
II.A.3.a-b
Panel-specific medical necessity (summary)
Policy includes distinct medical necessity statements for panels of five pathogens or fewer and panels of six or more; criteria and code/linkage requirements have been adjusted over time.
Summary of revision history and panel distinctions
When selecting testing for suspected respiratory infection, the policy emphasizes preference for targeted testing whenever it will provide sufficient diagnostic information for clinical management. Panel testing is appropriate only when targeted testing is not appropriate (will not provide sufficient information for the appropriate clinical management) and when the other panel-specific criteria are met (see Section I requirements for panels of five pathogens or fewer and additional rules for larger panels).
Providers must ensure the panel chosen aligns with the intended use and validated population for the registered test and that the panel includes at least the minimum pathogens required for clinical decision making; if a focused, pathogen-specific test would answer the clinical question, the more limited targeted test should be used instead of a multi-pathogen panel.
The policy notes that the diagnostic value of multi-pathogen respiratory viral panels is limited when identification of a pathogen will not alter clinical management. Although PCR panels are highly sensitive and specific and can inform antiviral use, infection control, and reduce unnecessary antibiotic prescribing, identification of a specific virus often does not change individual patient care; therefore panels should not be used when results are unlikely to influence treatment or disposition.
Immunocompromised status and related diagnoses support medical necessity
The policy lists many immunocompromising diagnoses and transplant/therapy statuses that support medical necessity for respiratory viral PCR panels (see ICD‑10 list additions in revision history).
See Table 5 additions in revision history
Pre‑transplant allowance from I.A.2 and revision notes
Billing and Code Lists
Provider Responsibilities & Billing Alerts
Code & POS linkage required
Code and place-of-service (POS) linkage is required for medical necessity determinations for certain respiratory viral panel CPT/PLA codes. Verify that the CPT/PLA code billed is supported by an allowed POS (see Table 3) and by an appropriate ICD-10 diagnosis per the policy tables; tests billed without the required CPT+POS and diagnosis combinations may not meet medical necessity.
- Ensure billed CPT/PLA code is paired with an approved Place of Service from Table 3 when required.
- When Table 2 or Table 4 require specific diagnosis codes, include an applicable ICD-10 on the claim.
- Codes 0098U, 0099U, 0100U, 0115U and other listed CPTs are subject to POS/diagnosis linkage per revision history; verify current table assignments.
Denial risk for unmet criteria or missing documentation
Tests that do not meet the policy medical necessity criteria (sections I and II) or for which required documentation is missing are subject to denial. Common denial triggers include lack of clinical indication, failure to show why targeted testing was insufficient, and absence of required POS/diagnosis linkage when applicable.
- Claims lacking documentation that the test result would impact clinical management as required by I.B may be denied.
- Panels ordered when targeted testing would have been sufficient (per I.D) risk denial.
- Billing CPT codes without the corresponding POS or approved ICD-10 diagnosis listed in Tables 3–5 may be denied.
Documentation required in the medical record
Required documentation must be present in the medical record to support medical necessity. Maintain clear documentation of clinical indications, rationale for panel testing, and billing context (provider type and place of service).
- Document specific clinical indications/suspicion for the pathogen (I.G.1).
- Document specific reasons why a panel (rather than targeted testing) is being performed (I.G.2 and I.D).
- Document provider type/specialty and Place of Service (I.G.3).
- Retain records showing how test results would influence clinical management (I.B).
Preference for targeted testing
Use targeted testing when it will provide sufficient information for appropriate clinical management. Panel testing (multiple-pathogen panels) should be used only when targeted testing is not appropriate or insufficient, and when the panel includes the minimum pathogens required for clinical decision making.
- If targeted testing can identify the likely pathogen and guide treatment, order targeted tests instead of panels.
- When ordering a panel, document why targeted testing was insufficient and confirm the panel meets test performance and pathogen inclusion requirements (I.E, I.F).
Provider note — follow policy revisions for code/diagnosis/POS linkage
Policy revisions have clarified and added requirements tying CPT/PLA codes to specific diagnosis and place-of-service codes; providers should bill with the appropriate combinations and consult the most recent tables and revision notes when submitting claims.
- Refer to the latest revision dates (see policy history) for changes to Table 2, Table 3, and ICD-10 code lists.
- Billing practices changed over time (codes moved/added/deleted); verify current policy tables before claim submission.
How to Order & Documentation Expectations
Orderers must record indication, panel rationale, provider type and POS; larger panels need extra linkages
When ordering, document the clinical indication, the specific reason for choosing panel testing over targeted testing, and the provider type/specialty and place of service; larger panels (Table 2 codes) additionally require the POS or paired diagnosis codes specified in Tables 3–5.
- For panels of six or more targets, ensure the order includes the care setting (ED, inpatient, observation) or the qualifying diagnosis/clinical circumstance described in Section II.
- Attach supporting clinical notes to the laboratory order when possible.
Outpatient ≤5-target panels require documented indication when ordered by/without an ID specialist
For outpatient orders of panels with five or fewer targets, include the clinical indication when the test is ordered by an Infectious Disease specialist or when an ID specialist is not available; this supports the outpatient medical necessity criteria added in revisions.
- Document if the order was placed by an ID specialist or if ID consult was not available and why outpatient panel testing is still needed.
Exclusions and Limitations
Panels performed when the identification of a pathogen will not influence clinical management are not supported. If a targeted test (one or a small number of analytes) would provide the necessary information for decision-making, the targeted approach is preferred and panel testing is not covered.
For panels of five pathogens or fewer, the policy requires that targeted testing be inappropriate and that test results will impact clinical management and meet the other Section I requirements; panels done solely for broad surveillance or when results will not change patient care do not meet medical necessity.
The policy revision history documents removal of COVID-19–specific criteria in Section I.A (noted in the 08/21 revision). In the current policy window there are no standalone COVID-19 exclusions or criteria retained — COVID-19–specific language referenced in earlier versions has been deleted.
Key Terms
Testing Frequency Constraints
Clinical Background
Multiplex PCR respiratory viral panels (RVPs) detect nucleic acid (RNA or DNA) from multiple respiratory viruses, typically from nasal, nasopharyngeal, or oropharyngeal swabs. These assays can identify common viral causes of respiratory illness (for example, rhinovirus, parainfluenza, adenovirus, respiratory syncytial virus, human metapneumovirus, and influenza) and are generally highly sensitive and specific.
While PCR RVPs can assist with antiviral decisions, infection control, and reducing unnecessary antibiotic use—especially in immunocompromised or critically ill patients—routine identification of a specific virus does not always change individual patient management, so use should be guided by the clinical context and the policy’s medical necessity criteria.
Policy Revision Timeline
Policy developed (approval date 01/20) and initial content added including note to refer to CP.MP.183 for 2019‑novel coronavirus testing.
Policy split medical necessity statements to address panels of 5 or fewer versus 6 or more targets; added outpatient criteria for ≤5‑target panels and moved CPT codes 87632 and 87633 to a medically necessary table when billed with specific POS; added PLA codes 0098U, 0099U, 0100U, and 0115U as medically necessary when billed with POS codes in Table 3.
References reviewed and updated; reaffirmed split of medical necessity statements and outpatient indications for ≤5‑target panels; codes 87632/87633 retained in POS‑linked medically necessary table and PLA codes 0098U–0100U and 0115U listed as medically necessary when billed with POS in Table 3.
CPT/PLA codes 0098U, 0099U, and 0100U were deleted (removed) from the code set.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.